Compare DigitalOcean Holdings Inc (DOCN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DigitalOcean Holdings Inc vs TG Therapeutics Inc — how do they compare? DigitalOcean Holdings Inc trades at $134.82 (market cap $14.57B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: DigitalOcean Holdings Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, DigitalOcean Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DigitalOcean Holdings Inc for 43 Days and TG Therapeutics Inc for 16 Days on average.
| DOCN | TGTX | |
|---|---|---|
Market Cap | $14.57B | $8.16B |
Volume | 2,261,786 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $181.29 | $59.06 |
52-Week Low | $37.30 | $26.94 |
Typical Hold Time | 43 Days | 16 Days |
Enterprise Value | $15.33B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DigitalOcean (DOCN) trades at $134.82, up 5.92% today, showing strong momentum with three consecutive quarterly earnings beats. The stock exhibits bullish technical signals with RSI levels in oversold territory, while fundamentals reveal impressive revenue growth from $576M in 2022 to $901M in 2025, with net income turning positive at $259M. Recent announcements include new AI-focused Agent Droplets and a $725M equipment financing facility to support capacity expansion.
DOCN presents growth potential with strong analyst support (68% buy ratings) and a $172.73 consensus price target, though elevated valuation ratios (P/E 56.32, P/S 13.96) and negative shareholder equity pose risks. The company's AI-native cloud strategy shows promise, but execution risks and competitive pressures in the cloud infrastructure space require monitoring.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
